Associated Genetic Biomarkers
Activating transcription factor 1 (ATF1) is a gene that encodes a transcription factor protein that functions in regulating the expression of downstream target genes that affect growth, survival, and other cellular activities. Fusions, missense mutations, and silent mutations are observed in cancers such as breast cancer, intestinal cancer, and ovarian cancer.
ATF1 is altered in 1.92% of all cancers with sarcoma, head and neck cancer, atypical teratoid/rhabdoid tumor, connective and soft tissue neoplasm, and head and neck squamous cell carcinoma having the greatest prevalence of alterations .
The most common alterations in ATF1 are ATF1 N165S (0.00%), ATF1 D156N (0.00%), ATF1 E217Q (0.00%), and ATF1 G145D (0.00%) .
ATF1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ATF1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ATF1 status in the inclusion eligibility criteria most commonly target clear cell sarcoma of soft tissue .
The most frequent alteration to serve as an inclusion eligibility criterion is EWSR1-ATF1 Fusion .
Significance of ATF1 in Diseases
Clear Cell Sarcoma Of Soft Tissue +
ATF1 is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains ATF1 status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.